Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effective rituximab treatment in primary Sjogren's syndrome: A randomised,double-blind, placebo-controlled trial.

Trial Profile

Effective rituximab treatment in primary Sjogren's syndrome: A randomised,double-blind, placebo-controlled trial.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Sjogren's syndrome
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2012 Results assessing changes from baseline in immunoglobulin free light chain concentrations presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 04 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 May 2011 Interim results reporting the effects of treatment on BAFF levels were presented at the 12th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top